Biotech Values

[oc631]

Interesting company not sure I put much value on 435 (their share) so i would need to look at the rest of their pipeline more closely.

Considering the size of the oral Hep-C market, and Medivir's tiny market capitalization, it becomes obvious that the company would do tremendously well if TMC435 is used in GT1 treatment-naive patients.